title: Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma.
abstract: We studied 174 consecutive patients with relapsed refractory multiple myeloma (MM) enrolled on a phase II clinical trial of pomalidomide plus low-dose dexamethasone at Mayo Clinic. Extramedullary disease (EMD) was present at the time of trial entry in 7.5% (13 of 174 patients). The rate of EMD in the first 3 years following diagnosis of MM was 3%. The response of EMD to pomalidomide plus low-dose dexamethasone included two complete and two partial responses among the 13 patients (response rate, 31%). Overall survival measured from trial entry was significantly shorter for patients with treatment-emergent EMD compared with those who did not have EMD, (median 16 months versus not reached, P=0.002).
authors.affiliation: Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
authors.forename: K Detweiler
authors.initials: KD
authors.lastname: Short
authors.forename: S V
authors.initials: SV
authors.lastname: Rajkumar
authors.forename: D
authors.initials: D
authors.lastname: Larson
authors.forename: F
authors.initials: F
authors.lastname: Buadi
authors.forename: S
authors.initials: S
authors.lastname: Hayman
authors.forename: A
authors.initials: A
authors.lastname: Dispenzieri
authors.forename: M
authors.initials: M
authors.lastname: Gertz
authors.forename: S
authors.initials: S
authors.lastname: Kumar
authors.forename: J
authors.initials: J
authors.lastname: Mikhael
authors.forename: V
authors.initials: V
authors.lastname: Roy
authors.forename: R A
authors.initials: RA
authors.lastname: Kyle
authors.forename: M Q
authors.initials: MQ
authors.lastname: Lacy
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D003907:Dexamethasone; D006801:Humans; D015994:Incidence; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology*; D015996:Survival Rate; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D013792:Thalidomide; D003907:Dexamethasone; C467566:pomalidomide